Publications
- Pertuzumab in the neoadjuvant treatment of breast cancer2021 | First Faculty of Medicine
- Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE2021 | First Faculty of Medicine
- Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysisPublication without faculty affiliation
- Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic2023 | First Faculty of Medicine
- Preservation of fertility in young patients with breast cancer, including BRCA1, BRCA2 mutation carriers2023 | First Faculty of Medicine
- Trastuzumab deruxtecan in the treatment of patients with metastatic HER2‑low breast cancer2023 | First Faculty of Medicine
- Ultrasound appearance and targeted therapy of symptomatic neural lesions in the breast and chest wall after breast cancer surgery2023 | First Faculty of Medicine
- Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers2022 | First Faculty of Medicine
- Komentář ke studii2022 | First Faculty of Medicine
- Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer2022 | First Faculty of Medicine
Loading network view...